These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25374321)

  • 1. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
    Thorarensen A; Kaila N
    Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
    Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
    Norman P
    Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
    Riccaboni M; Bianchi I; Petrillo P
    Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syk inhibitors with high potency in presence of blood.
    Thoma G; Blanz J; Bühlmayer P; Drückes P; Kittelmann M; Smith AB; van Eis M; Vangrevelinghe E; Zerwes HG; Che JJ; He X; Jin Y; Lee CC; Michellys PY; Uno T; Liu H
    Bioorg Med Chem Lett; 2014 May; 24(10):2278-82. PubMed ID: 24726806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respivert's multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449.
    Norman P
    Expert Opin Ther Pat; 2014 Dec; 24(12):1397-407. PubMed ID: 25407284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
    Norman P
    Expert Opin Ther Pat; 2009 Oct; 19(10):1469-72. PubMed ID: 19552507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
    Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.
    Papp E; Tse JK; Ho H; Wang S; Shaw D; Lee S; Barnett J; Swinney DC; Bradshaw JM
    Biochemistry; 2007 Dec; 46(51):15103-14. PubMed ID: 18052078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
    Zhao H; Caflisch A
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic prospect of Syk inhibitors.
    Ruzza P; Biondi B; Calderan A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
    Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola.
    Moore WJ; Richard D; Thorarensen A
    Expert Opin Ther Pat; 2010 Dec; 20(12):1703-22. PubMed ID: 21073366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.